[go: up one dir, main page]

MX2019009818A - Polipéptidos de unión al receptor de transferrina diseñados. - Google Patents

Polipéptidos de unión al receptor de transferrina diseñados.

Info

Publication number
MX2019009818A
MX2019009818A MX2019009818A MX2019009818A MX2019009818A MX 2019009818 A MX2019009818 A MX 2019009818A MX 2019009818 A MX2019009818 A MX 2019009818A MX 2019009818 A MX2019009818 A MX 2019009818A MX 2019009818 A MX2019009818 A MX 2019009818A
Authority
MX
Mexico
Prior art keywords
transferrin receptor
receptor binding
binding polypeptides
engineered transferrin
polypeptides
Prior art date
Application number
MX2019009818A
Other languages
English (en)
Inventor
Yu Zuchero Joy
J Watts Ryan
Chen Xiaocheng
S Dennis Mark
Kariolis Mihalis
P Silverman Adam
Srivastava Ankita
C Wells Robert
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2019009818A publication Critical patent/MX2019009818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Aquí se proporcionan polipéptidos que se unen a un receptor de transferrina, métodos para generar dichos polipéptidos y métodos para usar los polipéptidos para dirigir una composición a una célula que expresa el receptor de transferrina.
MX2019009818A 2017-02-17 2018-02-15 Polipéptidos de unión al receptor de transferrina diseñados. MX2019009818A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762460692P 2017-02-17 2017-02-17
US201762543658P 2017-08-10 2017-08-10
US201762583314P 2017-11-08 2017-11-08
PCT/US2018/018371 WO2018152326A1 (en) 2017-02-17 2018-02-15 Engineered transferrin receptor binding polypeptides

Publications (1)

Publication Number Publication Date
MX2019009818A true MX2019009818A (es) 2019-10-14

Family

ID=61521837

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009818A MX2019009818A (es) 2017-02-17 2018-02-15 Polipéptidos de unión al receptor de transferrina diseñados.
MX2023001964A MX2023001964A (es) 2017-02-17 2019-08-16 Polipeptidos de union al receptor de transferrina dise?ados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001964A MX2023001964A (es) 2017-02-17 2019-08-16 Polipeptidos de union al receptor de transferrina dise?ados.

Country Status (35)

Country Link
US (7) US11795232B2 (es)
EP (2) EP4169937A1 (es)
JP (3) JP2020508049A (es)
KR (1) KR102755478B1 (es)
CN (1) CN110506055A (es)
AU (2) AU2018221731C1 (es)
BR (1) BR112019016989A2 (es)
CA (1) CA3053375A1 (es)
CL (1) CL2019002307A1 (es)
CO (1) CO2019008873A2 (es)
CR (1) CR20190372A (es)
DK (1) DK3583120T5 (es)
EC (1) ECSP19058592A (es)
ES (1) ES2932759T3 (es)
FI (1) FI3583120T3 (es)
HR (1) HRP20221505T1 (es)
HU (1) HUE060983T2 (es)
IL (2) IL307373A (es)
LT (1) LT3583120T (es)
MD (1) MD3583120T2 (es)
MX (2) MX2019009818A (es)
MY (1) MY205898A (es)
NZ (1) NZ756763A (es)
PE (1) PE20191551A1 (es)
PH (1) PH12019550147A1 (es)
PL (1) PL3583120T3 (es)
PT (1) PT3583120T (es)
RS (1) RS63818B1 (es)
SA (1) SA519402463B1 (es)
SG (1) SG11201907427YA (es)
SI (1) SI3583120T1 (es)
SM (1) SMT202200478T1 (es)
TW (1) TWI797106B (es)
UA (1) UA127985C2 (es)
WO (1) WO2018152326A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AR114077A1 (es) * 2018-01-10 2020-07-15 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina y usos de los mismos
BR112021002730A2 (pt) * 2018-08-16 2021-08-10 Denali Therapeutics Inc. proteínas bispecíficas engenheiradas
MX2021001976A (es) * 2018-08-22 2021-06-08 Denali Therapeutics Inc Polipéptidos anti-her2 y métodos de uso de los mismos.
WO2020172457A1 (en) 2019-02-20 2020-08-27 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP3947661A1 (en) * 2019-04-03 2022-02-09 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
WO2021133907A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
AU2021208482B2 (en) * 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN111110834A (zh) * 2020-02-24 2020-05-08 中国科学院昆明动物研究所 转铁蛋白或过表达转铁蛋白在制备治疗和/或预防溃疡性结肠炎的药物中的应用
JP2023536474A (ja) * 2020-07-30 2023-08-25 ユニヴァーシティ オブ ワシントン トランスフェリン受容体結合タンパク質
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
IL309346A (en) 2021-07-01 2024-02-01 Denali Therapeutics Inc Transferrin receptor-targeted oligonucleotide conjugates
EP4448563A1 (en) 2021-12-17 2024-10-23 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4562041A2 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
CN120112164A (zh) 2022-07-29 2025-06-06 瑞泽恩制药公司 包含修饰的转铁蛋白受体基因座的非人动物
IL318636A (en) 2022-07-29 2025-03-01 Regeneron Pharma Viral particles retargeted to transferrin receptor 1
IL318625A (en) 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
KR20250117488A (ko) * 2022-09-20 2025-08-04 다나-파버 캔서 인스티튜트 인크. 치료제의 표적화된 분해 및 전달을 위한 수용체-매개 내포작용
WO2024160736A1 (en) 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
WO2024206161A1 (en) 2023-03-24 2024-10-03 Denali Therapeutics Inc. Abeta-targeting proteins and methods of use
WO2024216244A2 (en) 2023-04-13 2024-10-17 Regenxbio Inc. Targeting aav capsids, methods of manufacturing and using same
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
US20250041455A1 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
FR2705194A1 (fr) 1993-05-21 1994-11-25 Transgene Sa Animal transgénique exprimant une transferrine d'origine humaine.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
JP2003513016A (ja) 1999-08-30 2003-04-08 ニューヨーク・ユニバーシティ レセプタータンパク質チロシンキナーゼのドメイン、およびそのリガンドの結晶構造
JP2003525038A (ja) 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
JP2001238681A (ja) 2000-03-03 2001-09-04 Japan Science & Technology Corp 共培養による血液脳関門再構築モデル
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2448746A1 (en) 2001-06-29 2003-01-09 Wyeth Methods and compositions useful for the prediction of blood-brain barrier permeation
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US20030074141A1 (en) 2001-10-15 2003-04-17 Camitro Corporation Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors
EP1545595B1 (en) * 2002-08-30 2010-07-07 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004094647A2 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005076011A2 (en) 2004-01-30 2005-08-18 Xenoport, Inc. Use of glut1 transporter expressed in blood brain barrier cells for screening for pharmacologically active substances
GB0403490D0 (en) 2004-02-17 2004-03-24 Daniolabs Ltd Screening methods
FR2871162B1 (fr) 2004-06-02 2007-06-29 Univ Paris 7 Denis Diderot Materiau de surface modifiee, son procede de preparation et ses utilisations
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8084254B2 (en) 2004-11-29 2011-12-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human blood brain barrier model
ATE548386T1 (de) 2005-01-05 2012-03-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
US8900865B2 (en) 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
JP5113332B2 (ja) 2005-12-19 2013-01-09 正美 丹羽 血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
EP2029621A2 (en) 2006-06-07 2009-03-04 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20080044847A1 (en) 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
SG173332A1 (en) 2006-08-01 2011-08-29 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
JP5959795B2 (ja) 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
ES2975748T3 (es) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
WO2009008725A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CA3052615A1 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010014622A2 (en) 2008-07-28 2010-02-04 Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) In vitro model for modulating the blood brain barrier and methods of screening
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
WO2010121766A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
AU2010269978B2 (en) 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
US8417465B2 (en) 2009-11-04 2013-04-09 Cfd Research Corporation Synthetic microfluidic blood-brain barrier
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
CA2815112A1 (en) 2010-10-29 2012-05-03 Javier Cote-Sierra Murine model of inflammation with il33 n-terminal domain deletion
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CN103339142B (zh) 2011-02-02 2016-08-10 公益财团法人微生物化学研究会 能够穿过血脑屏障的药物递送材料，和肽及其应用
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
JP2014514313A (ja) 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト 血液脳関門のｐＨ依存性通過のための方法及び構築物
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX340498B (es) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Polipeptido heterodimerizado.
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
EP2568051A1 (en) 2011-09-07 2013-03-13 Stallergenes S.A. Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
DK177327B1 (en) 2011-12-23 2013-01-14 Entomopharm Aps OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds
CN104204204A (zh) 2012-02-09 2014-12-10 中外制药株式会社 抗体的Fc区变异体
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
SG11201405468QA (en) 2012-03-14 2014-10-30 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
WO2013162050A1 (ja) 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
CN104334576B (zh) 2012-06-04 2019-02-19 诺华股份有限公司 位点特异性标记方法及由此产生的分子
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
US9513280B2 (en) 2012-08-28 2016-12-06 University Of Utah Research Foundation Microfluidic biological barrier model and associated method
SI2890712T1 (sl) * 2012-08-29 2019-08-30 F. Hoffmann-La Roche Ag Prenašalec prek krvno-možganske pregrade
US10590393B2 (en) 2012-11-08 2020-03-17 Wisconsin Alumni Research Foundation Retinoic acid enhanced human stem cell derived blood brain barrier model
US9932559B2 (en) 2012-11-16 2018-04-03 The Johns Hopkins University Platform for creating an artificial blood brain barrier
CA2890455A1 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP6433297B2 (ja) 2012-12-27 2018-12-05 中外製薬株式会社 ヘテロ二量化ポリペプチド
EP2971047A4 (en) 2013-03-15 2016-11-30 Alper Biotech Llc MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGEN AND USES THEREOF
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2978840B1 (en) 2013-03-26 2020-09-30 Biocant - Centro De Inovação Em Biotecnologia A human blood-brain barrier model derived from stem cells
TWI523945B (zh) 2013-03-29 2016-03-01 Nat Univ Chung Cheng Establishment of blood - brain barrier model in
RU2019108429A (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
CA3222990A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
AU2014273817B2 (en) 2013-05-31 2019-03-14 Zymeworks Bc Inc. Heteromultimers with reduced or silenced effector function
BR112016001782A2 (pt) 2013-08-02 2017-08-29 Hoffmann La Roche Proteína de fusão terapêutica
EP3035969B1 (en) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Peptidic nanodelivery composition targeting two receptors
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
MY176237A (en) 2013-11-21 2020-07-24 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
JP6616189B2 (ja) 2013-12-25 2019-12-04 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
RU2693438C2 (ru) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
RU2694659C2 (ru) 2014-01-06 2019-07-16 Ф. Хоффманн-Ля Рош Аг Одновалентные модули-переносчики через гематоэнцефалический барьер
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
AU2015220920B2 (en) 2014-02-19 2019-09-12 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
CN106573964B (zh) 2014-05-22 2021-07-16 皮里斯制药有限公司 新型特异性结合多肽及其用途
US20160002343A1 (en) 2014-06-11 2016-01-07 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP2995949A1 (en) 2014-09-09 2016-03-16 Institut Pasteur New in vitro blood brain barrier model
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
US11820975B2 (en) 2014-12-09 2023-11-21 National Research Council Of Canada Human blood brain barrier model
WO2016202343A1 (en) 2015-06-19 2016-12-22 Aalborg Universitet A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes
UA123053C2 (uk) * 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
CN114409783B (zh) 2015-06-24 2025-09-16 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017035119A1 (en) 2015-08-24 2017-03-02 National University Of Singapore Blood brain barrier model in a 3d co-culture microfluidic system
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
JP7676100B2 (ja) 2016-02-05 2025-05-14 ジェンマブ アクティーゼルスカブ 改善された内部移行特性を有する多重特異性抗原結合分子
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
US20200317749A1 (en) 2016-07-01 2020-10-08 Denali Therapeutics Inc. Albumin variants for enhanced serum half-life
WO2018011353A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
US11097010B2 (en) 2016-08-06 2021-08-24 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
WO2018117613A1 (ko) 2016-12-19 2018-06-28 한미약품 주식회사 뇌 표적 지속성 단백질 결합체
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
WO2018124121A1 (ja) 2016-12-26 2018-07-05 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
WO2018175383A1 (en) 2017-03-22 2018-09-27 Research Corporation Technologies, Inc. Engineered stable ch2 polypeptides
CA3061235A1 (en) 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
CA3072035A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CA3080351A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
AR114077A1 (es) 2018-01-10 2020-07-15 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina y usos de los mismos
KR20190114907A (ko) 2018-03-30 2019-10-10 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
CA3101202A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
BR112021002730A2 (pt) 2018-08-16 2021-08-10 Denali Therapeutics Inc. proteínas bispecíficas engenheiradas
MX2021001976A (es) 2018-08-22 2021-06-08 Denali Therapeutics Inc Polipéptidos anti-her2 y métodos de uso de los mismos.
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
JP7624919B2 (ja) 2018-10-16 2025-01-31 デナリ セラピューティクス インコーポレイテッド プログラニュリン関連障害を処置及びモニタリングするための方法
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CN113826015A (zh) 2018-12-10 2021-12-21 戴纳立制药公司 溶酶体贮积症的生物标志物及其使用方法
EP3947661A1 (en) 2019-04-03 2022-02-09 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
KR20220156526A (ko) 2020-02-19 2022-11-25 데날리 테라퓨틱스 인크. 조작된 항-her2 이중특이성 단백질
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法

Also Published As

Publication number Publication date
SA519402463B1 (ar) 2025-05-15
AU2018221731B2 (en) 2021-07-01
MY205898A (en) 2024-11-19
PH12019550147A1 (en) 2020-06-15
MD3583120T2 (ro) 2023-02-28
CO2019008873A2 (es) 2019-08-30
US20230235072A1 (en) 2023-07-27
FI3583120T3 (fi) 2023-01-13
US20240271327A1 (en) 2024-08-15
US20200223935A1 (en) 2020-07-16
IL268660A (en) 2019-10-31
AU2021240106B2 (en) 2023-09-07
SG11201907427YA (en) 2019-09-27
KR20190129868A (ko) 2019-11-20
US20240271326A1 (en) 2024-08-15
NZ756763A (en) 2023-04-28
CA3053375A1 (en) 2018-08-23
RS63818B1 (sr) 2023-01-31
AU2018221731C1 (en) 2021-11-18
US20240018253A1 (en) 2024-01-18
EP4169937A1 (en) 2023-04-26
JP2025083406A (ja) 2025-05-30
IL268660B2 (en) 2024-03-01
US12162948B2 (en) 2024-12-10
CN110506055A (zh) 2019-11-26
MX2023001964A (es) 2023-02-23
TW201843174A (zh) 2018-12-16
US20250297023A1 (en) 2025-09-25
LT3583120T (lt) 2022-12-27
JP2023100833A (ja) 2023-07-19
US20240141058A1 (en) 2024-05-02
HRP20221505T1 (hr) 2023-02-17
IL307373A (en) 2023-11-01
CR20190372A (es) 2019-10-17
US11912778B2 (en) 2024-02-27
DK3583120T3 (da) 2022-12-19
PL3583120T3 (pl) 2023-01-09
HUE060983T2 (hu) 2023-05-28
TWI797106B (zh) 2023-04-01
CL2019002307A1 (es) 2020-01-17
EP3583120B1 (en) 2022-10-05
BR112019016989A2 (pt) 2020-05-26
ECSP19058592A (es) 2019-08-30
PE20191551A1 (es) 2019-10-24
PT3583120T (pt) 2022-12-15
WO2018152326A1 (en) 2018-08-23
IL268660B1 (en) 2023-11-01
JP2020508049A (ja) 2020-03-19
EP3583120A1 (en) 2019-12-25
UA127985C2 (uk) 2024-03-06
SMT202200478T1 (it) 2023-01-13
SI3583120T1 (sl) 2023-02-28
AU2018221731A1 (en) 2019-09-19
DK3583120T5 (da) 2024-09-02
US11795232B2 (en) 2023-10-24
AU2021240106A1 (en) 2021-10-28
KR102755478B1 (ko) 2025-01-14
ES2932759T3 (es) 2023-01-25

Similar Documents

Publication Publication Date Title
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
PH12017502180A1 (en) Tau-binding antibodies
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
SG10201909716RA (en) Modified j-chain
MY205850A (en) Proteins binding bcma, nkg2d and cd16
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
MY198562A (en) Antibodies specifically binding pd-1 and their uses
SI3665192T1 (sl) Inženiring polipeptidov, ki se vežejo na receptorje za transferine
MX2019007021A (es) Anticuerpos il-11ra.
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
NZ629816A (en) Therapeutic peptides
PH12017502207B1 (en) Tau-binding antibodies
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
AU2015279552A8 (en) Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
EA201991922A1 (ru) Сконструированные полипептиды, связывающие трансферриновый рецептор
NZ766927A (en) Chimeric receptors and methods of use thereof
SG2014003362A (en) Stapling eif4e interacting peptides